Amgen, Inc. vs AngloGold Ashanti Limited — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while AngloGold Ashanti Limited trades at $100.45 (market cap $49.19B). The key difference: Amgen, Inc. is far larger — about 4.6× AngloGold Ashanti Limited's market cap, and AngloGold Ashanti Limited pays the higher dividend (4.65%). Which is the better fit depends on your goals.
| AMGN | AU | |
|---|---|---|
Market Cap | $225.71B | $49.19B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $128.26 |
52-Week Low | $271.18 | $52.15 |
Enterprise Value | $269.02B | $48.20B |
Dividend Yield | 2.42% | 4.65% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →